High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F

Table 1: Clinical features of patients* with CENP­F antibodies and reactivity with CENP­F (p­F) epitopes†
        Epitope; reactivity
Patient no. Sex Age Clinical feature p­F1 p­F2 p­F3 p­F4 p­F5 IP­TnT‡
1 F 49 Chronic hepatitis B + + + - - -
2 F 65 Ischemic colitis, systemic lupus erythematosus + - - - - -
3 M 42 Chronic renal allograft rejection + + + + + +
4 M 60 Lung cancer ND§ + + + ND +
5 F 54 Breast cancer + - - + + +
6 M 50 Crohn disease + + + + + +
7 F 62 Tonsil cancer + + + + + +
8 F 47 Breast cancer - - - + + +
9 F 60 Breast cancer - + + + + +
10 F 68 Liver dysfunction - - - - - -
11 F 63 Cerebral ischemia ND ND ND ND ND ND
12 F 62 Liver cirrhosis (hepatitis B virus) + - - - - -
13 F 40 Nasopharyngeal carcinoma - + + + + +
14 M 93 Systemic lupus erythematosus ND ND ND ND ND ND
15 M 77 Lung cancer - + + + + +
16 F 74 Pancreatic disease - - - - - -
17 F 64 Undifferentiated connective tissue disease + + + + + +
18 F 43 Chronic hepatitis C ND - - - ND -
19 F 56 Breast cancer + + + + + +
20 F 61 Breast cancer + + + + + +
21 F 59 Tracheal cancer - + + + + +
22 M 68 Stomach cancer - + + + + +
23 M 58 Waldenstrom's macroglobulinemia - + + + + +
24 M 65 Stomach cancer - + + + + +
25 M 54 Chronic rejection renal allograft - - - - - -
26 M 61 Hepatocellular carcinoma ND + - ND ND ND
27 F 55 Breast cancer + + + + + +
28 F 44 Ovarian cancer + + + + + +
29 M 58 Lung cancer - + + + + +
30 F 75 Lung cancer + + + + + +
31 F 72 Breast cancer + + + + + +
32 F 64 Breast cancer - - - + - +
33 F 50 Lung cancer ND ND ND + + +
34 F 76 Breast cancer + + + + + +
35 F 72 Prolactinoma/hepatitis - + + + + +
36 M 46 Arthralgia + + + + + +
*Patients 1 to 26 coincide with the patient identification in another published study of clinical features of patients with anti-CENP­F antibodies.6 An additional 8 patients (29 to 36) are included in this study of reactivity with recombinant CENP­F.
†p­F epitopes represent recombinant peptides amino acids 2192­3317 (F1), 5561­7126 (F2), 5892­6883 (F3), 7538­10116 (F4) and 9242­10076 (F5).
‡IP-TnT = immunoprecipitation and in vitro transcription and translation.
§ND = not determined.

[ Return to text ]

| CIM: October 1997 (vol 20, no 5) / MCE : octobre 1997 (vol 20, no 5) |
CMA Webspinners / >